(Q44879845)

English

9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 December 2017

9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium (English)

1 reference

Europe PubMed Central

7 December 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

Everett E Vokes

6

object named as

Everett E Vokes

1 reference

Europe PubMed Central

7 December 2017

author name string

Hedy L Kindler

1

1 reference

Europe PubMed Central

7 December 2017

Anjali Avadhani

2

1 reference

Europe PubMed Central

7 December 2017

Kurombi Wade-Oliver

3

1 reference

Europe PubMed Central

7 December 2017

Theodore Karrison

4

1 reference

Europe PubMed Central

7 December 2017

Sridhar Mani

5

1 reference

Europe PubMed Central

7 December 2017

publication date

1 August 2004

1 reference

Europe PubMed Central

7 December 2017

Investigational New Drugs

1 reference

Europe PubMed Central

7 December 2017

22

1 reference

Europe PubMed Central

7 December 2017

3

1 reference

Europe PubMed Central

7 December 2017

323-327

1 reference

Europe PubMed Central

7 December 2017

https://scigraph.springernature.com/pub.10.1023/b:drug.0000026259.28395.c2

0 references

The clinical development of 9-aminocamptothecin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2003.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CPT-11 in gastrointestinal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of topotecan administered five times daily in patients with advanced gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/B:DRUG.0000026259.28395.C2

1 reference

Europe PubMed Central

7 December 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44879845&oldid=2055080743"